ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Down 12.8% in November

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was the target of a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 1,840,000 shares, a drop of 12.8% from the November 15th total of 2,110,000 shares. Based on an average daily trading volume, of 292,900 shares, the days-to-cover ratio is presently 6.3 days.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ANIP. StockNews.com cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Raymond James upped their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective for the company. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price on the stock. Finally, Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.71.

ANI Pharmaceuticals Stock Up 0.1 %

ANI Pharmaceuticals stock opened at $56.59 on Monday. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -102.89 and a beta of 0.73. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals has a 52-week low of $51.79 and a 52-week high of $70.81. The firm has a 50 day moving average price of $58.01 and a two-hundred day moving average price of $60.29.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. The firm had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company’s revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.05 earnings per share. Equities analysts predict that ANI Pharmaceuticals will post 3.87 EPS for the current year.

Insider Buying and Selling

In related news, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at approximately $2,943,540. This represents a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Nikhil Lalwani sold 33,481 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the sale, the chief executive officer now owns 370,378 shares in the company, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 34,731 shares of company stock valued at $2,015,861. 12.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Texas Permanent School Fund Corp boosted its stake in ANI Pharmaceuticals by 1.3% in the second quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company’s stock valued at $852,000 after acquiring an additional 178 shares during the last quarter. Louisiana State Employees Retirement System boosted its holdings in shares of ANI Pharmaceuticals by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock worth $490,000 after acquiring an additional 200 shares during the period. Arizona State Retirement System raised its stake in shares of ANI Pharmaceuticals by 4.7% during the 2nd quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock valued at $299,000 after purchasing an additional 211 shares during the period. Thrivent Financial for Lutherans lifted its holdings in ANI Pharmaceuticals by 2.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after purchasing an additional 299 shares in the last quarter. Finally, New York State Teachers Retirement System lifted its holdings in ANI Pharmaceuticals by 1.7% during the 3rd quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock worth $1,439,000 after purchasing an additional 394 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.